Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBITDA (2018 - 2025)

Historic EBITDA for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$17.6 million.

  • Whitehawk Therapeutics' EBITDA fell 4115.38% to -$17.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.5 million, marking a year-over-year increase of 7482.15%. This contributed to the annual value of -$63.7 million for FY2024, which is 292.73% up from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' EBITDA is -$17.6 million, which was down 4115.38% from -$52.6 million recorded in Q2 2025.
  • Whitehawk Therapeutics' 5-year EBITDA high stood at $73.0 million for Q1 2025, and its period low was -$87.1 million during Q3 2021.
  • Moreover, its 5-year median value for EBITDA was -$16.2 million (2023), whereas its average is -$15.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 267438.67% in 2021, then surged by 49839.01% in 2025.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' EBITDA stood at -$16.6 million in 2021, then grew by 16.28% to -$13.9 million in 2022, then dropped by 16.49% to -$16.2 million in 2023, then fell by 12.76% to -$18.3 million in 2024, then rose by 3.72% to -$17.6 million in 2025.
  • Its EBITDA stands at -$17.6 million for Q3 2025, versus -$52.6 million for Q2 2025 and $73.0 million for Q1 2025.